SCHEMBL6801318

SCHEMBL6801318

CC(C(=O)Nc1ccc([N+](=O)[O-])cc1)c1ccccn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 10/20 0.55
GAA P10253 3/20 0.52
HTT P42858 1/20 0.52
KDR P35968 2/20 0.51
MEN1 O00255 8/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
LMNA P02545 3/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
MAPT P10636 3/20 0.48
HTR1E P28566 1/20 0.48
S1PR3 Q99500 1/20 0.48
TP53 P04637 1/20 0.48
MITF O75030 1/20 0.48
POLB P06746 1/20 0.48
SLC11A2 P49281 1/20 0.47
CRHBP P24387 1/20 0.46
CRHR2 Q13324 1/20 0.46
ALDH1A1 P00352 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6794045 0.81 CYP1A2 (0.48) KMT2AGAAMEN1NPC1RAB9A
SCHEMBL6625967 0.77 KMT2A (0.72) KMT2AGAAHTTMEN1NPC1
SCHEMBL6918119 0.76 MAPT (0.70) KMT2AGAAHTTMEN1NPC1
SCHEMBL15551124 0.76 CYP1A2 (0.57) KMT2AGAAHTTMEN1NPC1
SCHEMBL16592576 0.75 KDR (0.81) KMT2AHTTKDRMEN1NPC1
SCHEMBL6644087 0.74 NPC1 (0.55) KMT2AKDRMEN1NPC1RAB9A
SCHEMBL29111764 0.74 KMT2A (0.62) KMT2AGAAHTTMEN1NPC1
SCHEMBL29111851 0.74 KMT2A (0.62) KMT2AGAAHTTMEN1NPC1
SCHEMBL29111760 0.74 KMT2A (0.62) KMT2AGAAHTTMEN1NPC1
SCHEMBL987822 0.73 KMT2A (0.61) KMT2AGAAHTTMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed
CN-1478077-A Benzamide compounds as APO B secretion inhibitors ����ҩƷ��ҵ��ʽ���� 2004-02-25 CN disclosed
EP-1326835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-07-16 EP disclosed
WO-2002028835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 KMT2A 2457/4885GAA 977/4885HTT 2566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.